Molecules Engineered Against Oncogenic Proteins and Cancer

Discovery, Design, and Development

E. J. Corey, Yong-Jin Wu

• Publisher: Wiley
• Year: 2023
• Print ISBN: 9781394207084
• eBook ISBN: 9781394207091
• Edition: 1
• Topic: Medicine
• Subtopic: Pharmacology

Molecules Engineered Against Oncogenic Proteins and Cancer

A comprehensive review of the latest molecular advances in cancer treatment

Featuring 91 total small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved, Molecules Engineered Against Oncogenic Proteins and Cancer documents the recent scientific advances that have transformed one of medicine's most challenging areas—cancer treatment. Most of these inhibitors specifically block oncogene-induced carcinogenic proteins with results that have dramatically advanced the treatment of cancer. In addition, the structural formulas of more than 100 kinase/KRAS inhibitors in clinical trials are presented.

With a very well-known chemist as an author, Molecules Engineered Against Oncogenic Proteins and Cancer includes information on:

• Each molecule's structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action
• Mutated protein kinases as oncoproteins and targets for inhibition, along with the details of discovery for each antitumor antikinase agent
• History of oncoprotein inhibitors and their role in advancing the treatment and understanding of cancer
• The discovery process as a whole, effective strategies for innovation, ongoing challenges, and a glimpse of the future of the field

Combining the most significant recent discoveries in a unique and useful way, Molecules Engineered Against Oncogenic Proteins and Cancer is an essential resource for researchers and students in bioscience, medicine, chemistry, and oncology as well as for those at industrial companies involved in therapeutic discovery.

Table of contents

• Cover
• Title Page
• Copyright
• Contents
• Preface
• Chapter 1. Introduction
• Chapter 2. BCR-ABL Inhibitors
• Chapter 3. BTK Inhibitors
• Chapter 4. EGFR/HER Family Inhibitors
• Chapter 5. VEGFR/Multikinase Inhibitors
• Chapter 6. CDK4/6 Inhibitors
• Chapter 7. JAK Inhibitors
• Chapter 8. Allosteric TYK2 Inhibitors
• Chapter 9. ALK/multikinase Inhibitors
• Chapter 10. BRAF/Multikinase Inhibitors
• Chapter 11. MEK Inhibitors
• Chapter 12. RET/Multikinase Inhibitors
• Chapter 13. FGFR Inhibitors
• Chapter 14. PI3K Inhibitors
• Chapter 15. TRK/Multikinase Inhibitors
• Chapter 16. MET Inhibitors
• Chapter 17. KIT/PDGFR/Multkinase Inhibitors
• Chapter 18. FLT3 Inhibitors
• Chapter 19. mTOR Inhibitors
• Chapter 20. Other Kinase Inhibitors
• Chapter 21. KRAS Inhibitors
• Chapter 22. An Overview of the Discovery Process for Medically Useful Inhibitors of Oncogenic Protein Kinases
• Chapter 23. Targeted Molecular Anticancer Therapies – Successes and Challenges
• Appendix 1. First FDA Approvals by Year
• Appendix 2. Kinase/KRAS Inhibitors in Development
• Appendix 3. Visualization of Differentially Expressed Kinases in Cancer
• Appendix 4. M & A Transactions Driven by Oncology-focused Kinase and KRAS Inhibitors
• Appendix 5. Alphabetic List of Oncogenic Protein Inhibitors
• EULA